Daily Roundup

Hydrix Medical Lands Singapore Heart Centre Contract

Hydrix Ltd's subsidiary Hydrix Medical has secured a multi-year contract with Singapore's National Heart Centre, marking another win for the company's remote cardiac monitoring platform. The deal, valued at approximately A$0.625 million over three years, will generate around A$0.21 million in annual recurring revenue. The National Heart Centre will deploy Hydrix Medical's Implicity cloud-based platform to monitor patients with cardiac implants, with the technology expected to streamline clinician workflows and enable faster interventions through advanced analytics.

Maronan Metals Delivers Strong Silver-Lead Results

Over in the metals space, Maronan Metals is making solid progress on one of Australia's largest undeveloped silver deposits. The company's expansive 40,000-meter infill drilling program at the Maronan Underground Project continues to intersect strong silver-lead mineralisation, with some standout intercepts including 11.0 metres grading 10.3% lead and 116 grams per tonne silver. These results are feeding directly into a resource update planned for Q4 FY2027, a crucial milestone that will support completion of a Pre-feasibility Study and help de-risk the project's value proposition.

Beach Energy Expands Queensland Footprint

Beach Energy has significantly expanded its presence in Queensland's Taroom Trough through its joint venture with Omega Oil & Gas and Tri-Star E&P. The partnership has been awarded 1,138 square kilometers of new acreage, pushing their total operated area up by 63% to 2,947 square kilometers. The expansion gives the joint venture access to the highly prospective eastern flank of the basin, positioning them to enhance resource potential and development targets as they push forward with their appraisal program.

Echo IQ Navigates FDA Pathway for EchoSolv HF

Echo IQ Limited is working through FDA feedback on its EchoSolv HF device, which received a Not Substantially Equivalent determination on its 510(k) application. The good news: the FDA's concerns are narrowly focused on statistical analysis supporting clinical validation, with no issues flagged around the underlying technology itself. The company is exploring multiple pathways forward, including an administrative appeal, FDA Ombudsman review, or a new submission. Echo IQ remains confident that clearance remains achievable over the coming quarters.

FOS Capital Raises $1.55 Million

FOS Capital Limited has completed a $1.55 million placement, issuing 12.9 million shares at $0.12 each. Several directors have also committed to subscribe for an additional $310,000 worth of shares, pending shareholder approval at the upcoming Annual General Meeting. The fresh capital will fuel growth initiatives including the Queensland Schools Lighting Upgrade Program and continued expansion of ATS, while also bolstering the company's balance sheet to pursue emerging opportunities.